Literature DB >> 9166547

Growth and metastasis of surgical specimens of human breast carcinomas in SCID mice.

T Sakakibara1, Y Xu, H L Bumpers, F A Chen, R B Bankert, M A Arredondo, S B Edge, E A Repasky.   

Abstract

PURPOSE: We have studied the growth and metastatic potential of surgical specimens of breast carcinomas engrafted into the large abdominal (gonadal) fat pad of severe combined immunodeficient (SCID) mice. We present results of this study, details of the implantation protocol and histologic characterization of several of the tumor xenografts.
MATERIALS AND METHODS: We evaluated the growth within SCID mice of 48 breast carcinoma specimens derived from 46 patients (45 primary breast cancers or local recurrences and 3 regional metastatic lymph nodes) obtained from resected tissues at this Institute over a 3-year period. The growth of each transplant was assessed by histologic examination of the xenografts at various times after implantation or upon passage into additional mice.
RESULTS: We observed that placement of human breast tumors within the gonadal fat pad could result in tumors that grew either rapidly, slowly, or not at all. Of 48 tumors studied, 12 (25%), including one of the three lymph node-derived tumors, grew rapidly enough within some or all of the implanted mice (i.e., the tumors reached a diameter of 2-3 cm within 2-6 months) to allow repeated passage. Metastatic spread to the SCID mouse lung, liver, and/or diaphragm and other sites was observed with the xenografts derived from 8 of these 12 rapidly growing tumors. Tumors in a second category often took from 6 months to over 1 year to only double or triple in size. This slow-growth group consisted of 25 patients' tumors (53%), including the remaining two metastatic lymph node-derived tumors. These xenografts would usually maintain a slow growth rate even upon later passage into new animals. A third category consisted ofpatients' tumors (23%) that failed to grow at all (i.e., no evidence of tumor growth in any of the mice implanted), as discerned by histologic evaluation at various times after implantation. Histologic examination of tumor xenografts and metastatic tumors revealed considerable variation in histopathology among the different patients' tumors. DISCUSSION: Further examination of the heterogeneous properties of primary human breast carcinomas within SCID mice may provide a simple yet valuable new approach for the long-term study of human breast cancer biology. Importantly, use of the protocol described here can often permit the isolation of substantial quantities of human breast cancer cells for biochemical and molecular analyses. The ability to passage patients' breast tumors into large numbers of mice will permit the preclinical testing of new therapies for the treatment and prevention of this disease.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9166547

Source DB:  PubMed          Journal:  Cancer J Sci Am        ISSN: 1081-4442


  18 in total

Review 1.  Patient-Derived Xenograft Models in Breast Cancer Research.

Authors:  Deukchae Na; Hyeong-Gon Moon
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

2.  Growth characteristics and metastatic properties of human breast cancer xenografts in immunodeficient mice.

Authors:  S Visonneau; A Cesano; M H Torosian; E J Miller; D Santoli
Journal:  Am J Pathol       Date:  1998-05       Impact factor: 4.307

Review 3.  Human cancer growth and therapy in immunodeficient mouse models.

Authors:  Leonard D Shultz; Neal Goodwin; Fumihiko Ishikawa; Vishnu Hosur; Bonnie L Lyons; Dale L Greiner
Journal:  Cold Spring Harb Protoc       Date:  2014-07-01

Review 4.  Mouse models of myelodysplastic syndromes.

Authors:  Sarah H Beachy; Peter D Aplan
Journal:  Hematol Oncol Clin North Am       Date:  2010-04       Impact factor: 3.722

5.  Prospective identification of tumorigenic breast cancer cells.

Authors:  Muhammad Al-Hajj; Max S Wicha; Adalberto Benito-Hernandez; Sean J Morrison; Michael F Clarke
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-10       Impact factor: 11.205

6.  Local regulation of human breast xenograft models.

Authors:  Jodie M Fleming; Tyler C Miller; Matthew J Meyer; Erika Ginsburg; Barbara K Vonderhaar
Journal:  J Cell Physiol       Date:  2010-09       Impact factor: 6.384

Review 7.  Patient-derived human tumour tissue xenografts in immunodeficient mice: a systematic review.

Authors:  Ketao Jin; Lisong Teng; Yanping Shen; Kuifeng He; Zhenzhen Xu; Guangliang Li
Journal:  Clin Transl Oncol       Date:  2010-07       Impact factor: 3.405

8.  Influence of the implantation site on the sensitivity of patient pancreatic tumor xenografts to Apo2L/TRAIL therapy.

Authors:  Rohit Sharma; Sandra Buitrago; Rose Pitoniak; John F Gibbs; Leslie Curtin; Mukund Seshadri; Elizabeth A Repasky; Bonnie L Hylander
Journal:  Pancreas       Date:  2014-03       Impact factor: 3.327

9.  A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models.

Authors:  Xiaomei Zhang; Sofie Claerhout; Aleix Prat; Lacey E Dobrolecki; Ivana Petrovic; Qing Lai; Melissa D Landis; Lisa Wiechmann; Rachel Schiff; Mario Giuliano; Helen Wong; Suzanne W Fuqua; Alejandro Contreras; Carolina Gutierrez; Jian Huang; Sufeng Mao; Anne C Pavlick; Amber M Froehlich; Meng-Fen Wu; Anna Tsimelzon; Susan G Hilsenbeck; Edward S Chen; Pavel Zuloaga; Chad A Shaw; Mothaffar F Rimawi; Charles M Perou; Gordon B Mills; Jenny C Chang; Michael T Lewis
Journal:  Cancer Res       Date:  2013-06-04       Impact factor: 12.701

10.  Lung cancer xenografting alters microRNA profile but not immunophenotype.

Authors:  Paul N Bogner; Santosh K Patnaik; Rose Pitoniak; Eric Kannisto; Elizabeth Repasky; Bonnie Hylander; Sai Yendamuri; Nithya Ramnath
Journal:  Biochem Biophys Res Commun       Date:  2009-06-10       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.